Tenax Therapeutics pauses LEVEL-2 enrollment
The company temporarily paused enrollment to amend inclusion criteria and seek FDA Type C feedback after Phase 3 analyses showed benefit in sicker PH-HFpEF patients.
The company temporarily paused enrollment to amend inclusion criteria and seek FDA Type C feedback after Phase 3 analyses showed benefit in sicker PH-HFpEF patients.